Abstract 323P
Background
Ovarian cancer is a general phrase that may be applied to any malignancy that affects the ovaries and is one of the worst malignancies. Aside from the number of its population, the Asian population also has a very diverse culture and socioeconomic development. Pretreatment peripheral blood cell counts, including lymphocytes, monocytes, and neutrophils, are major prognostic indicators in various cancers. This study aimed to evaluate the role of NLR, PLR, and LMR as prognostic biomarkers in ovarian cancer among the Asian population in a meta-analysis design.
Methods
This study assessed the association between NLR, PLR, and LMR and ovarian cancer as prognostic biomarkers based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol. The literature research was performed by systematically searching PubMed, ScienceDirect, and Google Scholar using the search terms based on BOOLEAN operators. Revman software ver 5.4.1 was employed for all statistical analyses, and p-values<0.05 were considered statistically significant.
Results
This study included 17 studies conducted in various Asian countries according to inclusion and exclusion criteria. Significant results were found in both univariate and multivariate analysis for NLR, PLR, and LMR to overall survival [(Univariate) NLR: HR 2.04; 95% CI 1.61 – 2.58; p<0.001, PLR: HR 2.04; 95% CI 1.26 – 3.30; p<0.001, LMR: HR 0.53; 95% CI 0.40 – 0.72; p<0.001. (Multivariate) NLR: HR 1.65; 95% CI 1.22 – 2.22; p<0.001, PLR: HR 2.12; 95% CI 1.70 – 2.66; p<0.001, LMR: HR 0.54; 95% CI 0.37 – 0.80; p=0.002]. Significant results were also found in both univariate and multivariate analysis for NLR and PLR to disease-free survival [(Univariate) NLR: HR 2.19; 95% CI 1.36 – 3.54; p<0.001, PLR: HR 1.95; 95% CI 1.31 – 2.91; p<0.001. (Multivariate) NLR: HR 1.37; 95% CI 1.21 – 1.56; p<0.001, PLR: HR 1.78; 95% CI 1.45 – 2.17; p<0.001.
Conclusions
NLR, PLR, and LMR can be considered as prognostic biomarkers in ovarian cancer. Further studies are needed to re-evaluate these findings in the Asian population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
I.G.P. Supadmanaba.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract